D. Western Therapeutics Institute, Inc. provided consolidated earnings guidance for the year ending December 31, 2023. For the year ending December 31, 2023, the company expects net sales of JPY 400 million, operating loss of JPY 1,400 million and loss attributable to owners of parent of JPY 1,390 million or JPY 44.60 per share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
105 JPY | -1.87% | -4.55% | -25.53% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.53% | 21.74M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- 4576 Stock
- News D. Western Therapeutics Institute, Inc.
- D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023